SCHEMBL4008027

SCHEMBL4008027

Cc1n[nH]c2ccc(OS(=O)(=O)c3ccc(Cl)c(Cl)c3)cc12

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ APEX1 P27695 1/20 0.53
▸ FPR2 P25090 1/20 0.40
▸ PROKR1 Q8TCW9 1/20 0.40
▸ ALPL P05186 5/20 0.40
▸ ALPI P09923 5/20 0.40
▸ TTK P33981 2/20 0.37
▸ MAOB P27338 1/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ EDNRB P24530 1/20 0.35
▸ EDNRA P25101 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ MAPK8 P45983 1/20 0.35
▸ IDO1 P14902 1/20 0.35
▸ DYRK1A Q13627 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4006545 0.95 APEX1 (0.50) APEX1FPR2PROKR1ALPLALPI
SCHEMBL4015098 0.88 APEX1 (0.56) APEX1FPR2PROKR1ALPLALPI
SCHEMBL4008175 0.85 APEX1 (0.53) APEX1ALPLALPITTKJAK2
SCHEMBL4007257 0.85 APEX1 (0.53) APEX1FPR2PROKR1ALPLALPI
SCHEMBL4007111 0.82 APEX1 (0.52) APEX1FPR2PROKR1ALPLALPI
SCHEMBL4006003 0.82 APEX1 (0.53) APEX1ALPLTTKALDH1A1MAPT
SCHEMBL4004276 0.82 APEX1 (0.50) APEX1ALPLALPITTKJAK2
SCHEMBL4008113 0.81 APEX1 (0.49) APEX1TTKJAK2MAPK8
SCHEMBL4005400 0.81 APEX1 (0.46) APEX1DYRK1A
SCHEMBL4008318 0.81 APEX1 (0.50) APEX1FPR2PROKR1ALPLALPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473701-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2009-01-06 — — US disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 — — US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 — — US disclosed
EP-1487803-A1 INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY Aventis Pharma S.A. (FR) 2004-12-22 — — EP disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 — — US disclosed
WO-2003078402-A1 INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY AVENTIS PHARMA S.A. (FR) 2003-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 APEX1 2215/4885FPR2 3158/4885PROKR1 3476/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 APEX1 2168/4885FPR2 3367/4885PROKR1 3971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback